Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

15th International Workshop on Chronic Lymphocytic Leukaemia (iwCLL 2013) /
The economic burden of CLL treatment now and in the future

9th - 11th Sep 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.11.13
Views: 3689

Dr George Follows - Addenbrooke’s Hospital, Cambridge, UK

This interesting presentation addresses the important question of whether health care systems can afford the new treatments emerging in CLL. What is clearly good for patient care provides a challenge for the health economy.

Dr Follows explains how cost-effectiveness is calculated, eg, according to Quality Adjusted Life Years – QALY, and Incremental Cost-Effectiveness Ratio - ICER.

He outlines the challenges of calculating cost-effectiveness for CLL drug regimens, including how similar patients in clinic are from the clinical trial study population.

He also addresses the balance needed in health economics in CLL between life expectancy, age and co-morbidities.


Content taken from a Mundipharma sponsored satellite symposium at iwCLL 2013 as part of the official programme.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation